Want to join the conversation?
$VRTX said the U.S. FDA accepted a supplemental New Drug Application for review for the use of its ORKAMBI drug in people with cystic fibrosis, a type of genetic disease, ages 6 to 11 who have two copies of the F508del mutation. The FDA granted the company's request for Priority Review of this sNDA, and a target review date of September 30, 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?